Gynecologic Cancers Successfully Treated Using IsoRay's Cesium-131 Will Be Presented by Dr. Jonathan Feddock Saturday Night While at the Society of Gynecologic Oncology Convention (SGO)

RICHLAND, WA--(Marketwired - Mar 24, 2015) - IsoRay Inc. (NYSE MKT: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a dinner presentation on March 28 by Dr. Jonathan Feddock describing the use, procedure and outstanding results in treating gynecologic cancers utilizing Cesium-131. IsoRay will have booth #516 at the 2015 Annual Meeting of the Society of Gynecologic Oncology (SGO). The annual meeting will take place March 28-31, 2015 at the Chicago Hilton in Chicago, Illinois.

According to IsoRay CEO Dwight Babcock, "With the recently published and peer-reviewed results for gynecologic cancer, we are seeing a growing level of interest by gynecologic oncologists due to the significant results being achieved using Cesium-131. Cesium-131's reported success in treating primary as well as recurrent gynecologic cancers that have not responded to other treatments continues to get the attention of physicians who need new treatment options."

IsoRay is very pleased to have Dr. Feddock, an industry leader who practices at University of Kentucky HealthCare, discuss the success, methods and new approaches being implemented in brachytherapy.

Mr. Babcock added, "The medical community is continually being shown the unique ability of IsoRay' s Cesium-131 (Cs-131) seeds, seed sutured, seeded mesh and GliaSite^® system for the treatment of a wide array of cancers throughout the body. Medical thought leaders recognize the need for a new powerful weapon in the battle against cancer and we believe Cesium-131 is that solution. Our products offer an important advance over previous brain, head and neck, lung, prostate, abdominal wall and gynecological cancer treatments. We are extremely excited that published studies, posters and abstracts continue to be released showing positive results realized in treating metastasized brain cancers, gynecological cancers, lung cancer and prostate cancer using Cs-131 or GliaSite^®."

IsoRay's Cesium-131 sutured seeds, stranded mesh and the GliaSite^® radiation therapy system each give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after tumor removal. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy tissue as well as critical structures compared to other alternative treatments. IsoRay's cancer fighting products reduce the ability of the tumor to recur, which means important benefits for patients in longevity as well as quality of life.

IsoRay is the exclusive manufacturer of Cesium-131. Cesium-131 is the first new isotope to be available in seed form for brachytherapy in approximately 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).

In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several new implantable devices. IsoRay also distributes the GliaSite® radiation therapy system, used to treat brain cancers.

About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.

Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems, future demand for IsoRay's existing and planned products, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether the use of our products will increase or continue, whether additional studies will be published or presented with favorable outcomes from treatment with our products, whether we will continue to receive support from industry leaders, whether awareness of our products in the medical community will continue or increase, whether future studies of treatment of various cancers using our products will have favorable results, whether awareness and adoption of our products by gynecologic oncologists will continue or grow, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of IsoRay's products, changing levels of demand for IsoRay's current and proposed future products, IsoRay's ability to reduce or maintain expenses while increasing sales, patient results achieved using our products in both the short and long term, success of future research and development activities, patient results achieved when Cesium-131 is used for the treatment of cancers and malignant diseases beyond prostate cancer, IsoRay's ability to successfully manufacture, market and sell its products, IsoRay's ability to manufacture its products in sufficient quantities to meet demand within required delivery time periods while meeting its quality control standards, the success of our sales and marketing efforts, IsoRay's ability to enforce its intellectual property rights, changes in reimbursement rates, changes in laws and regulations applicable to our products, whether additional studies and protocols are released and support the conclusions of past studies and protocols, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in their various forms, continued compliance with ISO standards as audited by BSI, and other risks detailed from time to time in IsoRay's reports filed with the SEC.